Treatment patterns, use of healthcare resources, and clinical characteristics of patients with castration-resistant prostate cancer (mCRPC) in Colombia: Preliminary analysis from ProColombia RC study.

Abstract

11059 Background: The clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients in Colombia remain poorly understood, particularly regarding their clinical profiles, stage at diagnosis, treatment options, and healthcare resource utilization (HRU). This study aims to describe real-world treatment patterns and HRU in mCRPC patients. Methods: This is a non-interventional, multicentre, retrospective study in mCRPC patients treated at reference centers across Colombia from Jan/2017 to Jun/2023. Data on demographic and clinical characteristics, treatment history, and (HRU) were extracted from electronic medical records. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Results: We present the Interim findings from the first 130 of the 380 patients we plan to enroll. The median follow-up was 70.0 months (IQR 46.8–136.1). The median age was 68y (IQR 61–73), with 86.2% residing in urban areas. Comorbidities were hypertension (64.6%) and type 2 diabetes (22.3%); 10.8% reported a family history of PC. Upon diagnosis, 54.6% had a Gleason grade of 4 or 5, and 82.7% passed through a metastatic hormone-sensitive prostate cancer (mHSPC) scenario and 47.7% of those mHSPC patients had high-volume disease. In the mCRPC setting, 14.6% had visceral metastases, while 78.4% had bone-predominant disease. In the first-line treatment, 73.8% received androgen receptor pathway inhibitors (ARPI) and 25.4% underwent taxane-based chemotherapy. Among the 81 patients (62.3%) who received second-line therapy, 27.1% received ARPI, 59.3% received taxane-based chemotherapy, 9.9% were treated with Radium-223, and 3.7% received PSMA-Lutetium. The median PFS in the first-line setting was 16.8 months (95%CI:13.0–20.7), with a median OS of 39.2 months (95%CI:32.6–45.9). Only 31% of patients were tested for HRR and MSI, with median OS from mCRPC diagnosis being 59.2 months (95%CI:34.6–83.7) for those tested versus 39.5 months (95%CI:32.8–46.1) for those not tested, a statistically significant difference (p=0.016). In terms of healthcare utilization, 60.0% required palliative radiation therapy, and 52.3% consulted with a palliative care specialist; 20.8% required at least one emergency consultation due to cancer-related issues. Conclusions: This study represents the first comprehensive report on the demographic, clinical, treatment patterns, and HRU of mCRPC patients in Colombia. The significant survival differences based on biomarker testing highlight quality of care that patients received. Standardized PC management protocols, developed collaboratively by multidisciplinary teams and multiple institutions in Colombia, could enhance patient outcomes and healthcare efficiency across the country.